INVIVYD INC

Invivyd Inc. has announced a bold new direction, shifting its focus from COVID-19 treatments to developing a monoclonal antibody for measles, a move that could redefine its trajectory but also poses significant risks and strategic considerations.

Invivyd, Inc. has secured a $30 million non-dilutive loan facility with Silicon Valley Bank to support its research and development of COVID-19 treatments and prevention.